Sunday, November, 27, 2022 07:55:44

Eurofins, a renowned company providing laboratory testing and support services, reportedly announced that in addition to America and Germany, as previously discussed, the company is now offering testing to detect SARS-COV-2 in Spain, France, and Brazil, with the Netherlands projected to initiate processing samples very soon.

Global capacity generated is presently about 10,000 trials per day split equally between America and Europe. The Eurofins teams are continuously putting all their efforts to increase the capacity owing to government requests. The capacity is thus estimated to increase to more than 15,000 trials each day from Monday, 23rd March 2020, and substantially more by 01 April 2020 since new testing methods and sites are added.

Eurofins laboratories are operating closely with public health regulatory bodies across the globe and also following their priorities to help medical professionals and hospitals tackling this severe health crisis.

Recently, five laboratories started the work of testing in France for SARS-CoV-2. Eurofins Biomnis’ laboratories, in particular, initiated testing for SARS-CoV-2 through a test they developed and validated successfully after gaining approval from public health authorities.

As a part of this initiative to help Healthcare authorities, Eurofins Biomnis is allowing French hospitals to free up the capacity to conduct SARS-CoV-2 trials on-site at less turnaround times by also providing outsourcing for infectious disease trials. In Spain, Eurofins Megalab Madrid also initiated trials for COVID-19 in this week. Eurofins Brazil also began COVID-19 trials through its Clinical Laboratory Centro de Genomas from 11th March 2020.

Along with these developments, Eurofins Technologies, a rapidly growing provider of diagnostic technologies in molecular detection methods as well as in the field of immunoassays, is concluding the development and further preparing to initiate validating novel SARS-CoV-2 clinical trial kits as well as testing kits to detect SARS-CoV2 in the environmental swabs of surfaces as well as in feed or food samples.


Source credit: